Potential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria

Cell Biochemistry and Biophysics

Volumn 65, Issue 3, 2013, Pages 321-333

  Nowak, Jacek ^a   Wozniak, Jolanta ^a   Mendek Czajkowska, Ewa ^a   Dlugokecka, Agnieszka ^a   Mika Witkowska, Renata ^a   Rogatko Koros, Marta ^a   Graczyk Pol, Elzbieta ^a   Marosz Rudnicka, Anna ^a   Dziopa, Joanna ^a   Golec, Agnieszka ^a   Kopec Szlezak, Joanna ^a   Warzocha, Krzysztof ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Apoptosis; Hematopoietic stem cell; HLA DR expression; MHC molecules; Paroxysmal nocturnal hemoglobinuria; PNH clone domination; PNH clone selection; Regulatory T cells; Self peptide presentation

Indexed keywords

EID: 84875211831     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9435-1     Document Type: Article

References (71)

1. Takeda, J., Miyata, T., Kawagoe, K., et al. (1993). Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell, 73, 703-711.
2. Crosby, W. H., & Dameshek, W. (1950). Paroxysmal nocturnal hemoglobinuria: the mechanism of hemolysis and its relation to the coagulation mechanism. Blood, 5, 822-842.
3. Holguin, M. H., Wilcox, L. A., Bernshaw, N. J., Rosse, W. F., & Parker, C. J. (1989). Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. Journal of Clinical Investigation, 84, 1387-1394.
4. Bessler, M., & Fehr, J. (1991). Fc III receptors (FcRIII) on granulocytes: a specific and sensitive diagnostic test for paroxysmal nocturnal hemoglobinuria (PNH). European Journal of Haematology, 47, 179-184.
5. Boccuni, P., Del Vecchio, L., Di Noto, R., & Rotoli, B. (2000). Glycosyl phosphatidylinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. Critical Reviews in Oncology and Hematology, 33, 25-43.
6. Hillmen, P., Lewis, S. M., Bessler, M., Luzzatto, L., & Dacie, J. V. (1995). Natural history of paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 333, 1253-1258.
7. Parker, C., Omine, M., Richards, S., et al. (2005). Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood, 106, 3699-3709.
8. Kawagoe, K., Kitamura, D., Okabe, M., et al. (1996). Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood, 87, 3600-3606.
9. Ware, R. E., Nishimura, J., Moody, M. A., Smith, C., Rosse, W. F., & Howard, T. A. (1998). The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood, 92, 2541-2550.
10. van Paridon, P. A., Gadella, T. W. J., Jr, Somerharju, P. J., & Wirtz, K. W. A. (1987). On the relationship between the dual specificity of the bovine brain phosphatidylinositol transfer protein and membrane phosphatidylinositoi levels. Biochimica et Biophysica Acta, 903, 68-77.
11. Mejillano, M., Yamamoto, M., Rozelle, A. L., Sun, H. Q., Wang, X., & Yin, H. L. (2001). Regulation of apoptosis by phosphatidylinositol 4, 5-bisphosphate inhibition of caspases, and caspase inactivation of phosphatidylinositol phosphate 5-kinases. Journal of Biological Chemistry, 276, 1865-1872.
12. Luzzatto, L., Bessler, M., & Rotoli, B. (1997). Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell, 88, 1-4.
13. Luzzatto, L., & Bessler, M. (1996). The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Current Opinions in Hematology, 3, 101-110.
14. Young, N. S. (1992). The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated. Blood, 79, 1385-1392.
15. Selvaraj, P., Dustin, M. L., Silber, R., Low, M. G., & Springer, T. A. (1987). Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. Journal of Experimental Medicine, 166, 1011-1025.
16. Selvaraj, P., Plunkett, M. L., Dustin, M., Sanders, M. E., Shaw, S., & Springer, T. A. (1987). The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature, 326, 400-403.
17. Marsh, J. C., & Elebute, M. O. (2003). Stem cells in paroxysmal nocturnal haemoglobinuria and aplastic anaemia: increasing evidence for overlap of haemopoietic defect. Transfusion Medicine, 13, 377-386.
18. Tiu, R., & Maciejewski, J. P. (2006). Immune pathogenesis of paroxysmal nocturnal hemoglobinuria. International Journal of Hematology, 84, 113-117.
19. Maciejewski, J. P., Sloand, E. M., Sato, T., Anderson, S., & Young, N. S. (1997). Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood, 89, 1173-1181.
20. Maciejewski, J. P., Follmann, D., Nakamura, R., et al. (2001). Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood, 98, 3513-3519.
21. Shichishima, T., Okamoto, M., Ikeda, K., et al. (2002). HLA class II haplotype and quantitation of WT1 RNAin Japanese patients with paroxysmal nocturnal hemoglobinuria. Blood, 100, 22-28.
22. Lombardi, M. L., Terrazzano, G., Cosentini, E., et al. (2008). Paroxysmal nocturnal hemoglobinuria: significant association with specific HLA-A, -B, -C, and -DR alleles in an Italian population. Human Immunology, 69, 202-206.
23. Nowak, J., Mika-Witkowska, R., Polak, M., et al. (2008). Allele and extended haplotype polymorphism of HLA-A, C, B, DRB1 and DQB1 loci in polish population and genetic affinities to other populations. Tissue Antigens, 71, 193-205.
24. Nowak, J., Mika-Witkowska, R., Mendek-Czajkowska, E., et al. (2011). The patterns of MHC association in aplastic and non-aplastic paroxysmal nocturnal hemoglobinuria. Archivum Immunologiae et Therapiae Experimentalis, 59, 231-238.
25. Nowak, J., Mika-Witkowska, R., Mendek-Czajkowska, E., et al. (2010). Association of HLA haplotypes with paroxysmal nocturnal hemoglobinuria. Transplantation Proceedings, 42, 3266-3270.
26. Nowak, J., Juszczynski, P., & Warzocha, K. (2009). The role of major histocompatibility complex polymorphisms in the incidence and outcome of non-Hodgkin lymphoma. Current Immunology Reviews, 5, 300-310.
27. Marsh, S. G. E., Parham, P., & Barber, L. D. (2000). The HLA Facts Book. San Diego, CA: Academic Press.
28. Derbinski, J., & Kyewski, B. (2010). How thymic antigen presenting cells sample the body's self-antigens. Current Opinions in Immunology, 22, 592-600.
29. Danzl, N. M., Donlin, L. T., & Alexandropoulos, K. (2010). Regulation of medullary thymic epithelial cell differentiation and function by the signaling protein Sin. Journal of Experimental Medicine, 207, 999-1013.
30. Zhang, J., & Li, L. (2008). Stem cell niche-microenvironment and beyond. Journal of Biological Chemistry, 283, 9499-9503.
31. Dent, A. L., & Kaplan, M. H. (2008). T cell regulation of hematopoiesis. Frontiers in Bioscience, 13, 6229-6236.
32. Ogawa, M., & Matsunaga, T. (1999). Humoral regulation of hematopoietic stem cells. Annals of the New York Academy of Sciences, 872, 17-23.
33. Terrazzano, G., Sica, M., Becchimanzi, C., et al. (2005). T cells from paroxysmal nocturnal haemoglobinuria (PNH) patients show an altered CD40-dependent pathway. Journal of Leukocyte Biology, 78, 27-36.
34. Coluzzi, S., Biffoni, M., Pasqualetti, D., et al. (2004). Production of interferon-gamma by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: relationship with clinical status. British Journal of Haematology, 124, 685-690.
35. Urbieta, M., Barao, I., Jones, M., et al. (2010). Hematopoietic progenitor cell regulation by CD4+CD25+T cells. Blood, 115, 4934-4943.
36. Lee, J. H., Wang, C., & Kim, C. H. (2009). FoxP3+ regulatory T cells restrain splenic extramedullary myelopoiesis via suppression of hemopoietic cytokine-producing T cells. Journal of Immunology, 183, 6377-6386.
37. Sutherland, D. R., Anderson, L., & Keeney, M. (1996). The ISHAGE guidelines for CD34+ cell determination by flow cytometry. Journal of Hematotherapy, 5, 213-236.
38. Davis, K., Abrams, B., Hoffman, R. A., & Bishop, J. E. (1996). Quantitation and palence of antibodies bound to cells. Cytometry Supplement, 8, 150.
39. Kubo, R. T., Sette, A., Grey, H. M., et al. (1994). Definition of specific peptide motifs for four major HLA-A alleles. Journal of Immunology, 152, 3913-3924.
40. Papadopoulos, K. P., Colovai, A. I., Maffei, A., Jaraquemada, D., Suciu-Foca, N., & Harris, P. E. (1996). Tissue-specific self-peptides bound by major histocompatibility complex class I molecules of a human pancreatic beta-cell line. Diabetes, 45, 1761-1765.
41. Chicz, R. M., Urban, R. G., Gorga, J. C., Vignali, D. A., Lane, W. S., & Strominger, J. L. (1993). Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. Journal of Experimental Medicine, 178, 27-47.
42. Vogt, A. B., Kropshofer, H., Kalbacher, H., et al. (1994). Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. Journal of Immunology, 153, 1665-1673.
43. Kirschmann, D. A., Duffin, K. L., Smith, K. E., et al. (1995). Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. Journal of Immunology, 155, 5655-5662.
44. Verreck, F. A., Elferink, D., Vermeulen, C. J., et al. (1995). DR4Dw4/DR53 molecules contain a peptide from the autoantigen calreticulin. Tissue Antigens, 45, 270-275.
45. Verreck, F. A., van de Poel, A., Drijfhout, J. W., Amons, R., Coligan, J. E., et al. (1996). Natural peptides isolated from Gly86/Val86-containing variants of HLA-DR1, -DR11, -DR13, and -DR52. Immunogenetics, 43, 392-397.
46. Hickman, H. D., Luis, A. D., Buchli, R., et al. (2004). Toward a definition of self: proteomic evaluation of the class I peptide repertoire. Journal of Immunology., 172, 2944-2952.
47. Protein Information Resource Georgetown University Medical Center. (2011). http://pir. georgetown. edu/pirwww/search/peptide. shtml.
48. Friede, T., Gnau, V., Jung, G., Keilholz, W., Stevanović, S., & Rammensee, H. G. (1996). Natural ligand motifs of closely related HLA-DR4 molecules predict features of rheumatoid arthritis associated peptides. Biochimica et Biophysica Acta, 1316, 85-101.
49. Papadopoulos, K. P., Suciu-Foca, N., Hesdorffer, C. S., et al. (1997). Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood, 90, 4938-4946.
50. Kappler, J. W., Roehm, N., & Marrack, P. (1987). T cell tolerance by clonal elimination in the thymus. Cell, 49, 273-280.
51. Rosse, W. F., & Dacie, J. V. (1966). Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells: I. The sensitivity of PNH red cells to lysis by complement and specific antibody. Journal of Clinical Investigations, 45, 736-748.
52. Maciejewski, J. P., Young, N. S., Yu, M., Anderson, S. M., & Sloand, E. M. (1996). Analysis of the expression of glycosylphosphatidylinositol anchored proteins on platelets from patients with paroxysmal nocturnal hemoglobinuria. Thrombosis Research, 83, 433-447.
53. Yamaguchi, M., McSweeney, P. A., Kimball, L., et al. (1999). Recognition of major histocompatibility complex class II antigens by two anti-HLA-DR monoclonal antibodies on canine marrow cells correlates with effects on in vitro and in vivo hematopoiesis. Transplantation, 68, 1161-1171.
54. Yamaguchi, M., Nadler, S., Lee, J. W., & Deeg, H. J. (1999). Induction of negative regulators of haematopoiesis in human bone marrow cells by HLA-DR cross-linking. Transplantation Immunology, 7, 159-168.
55. Lee, J. W., Gersuk, G. M., Kiener, P. A., Beckham, C., Ledbetter, J. A., & Deeg, H. J. (1997). HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. Journal of Immunology, 159, 3211-3219.
56. Scheffold, A., Murphy, K. M., & Höfer, T. (2007). Competition for cytokines: Treg cells take all. Nature Immunology, 8, 1285-1287.
57. Zeng, W., Miyazato, A., Chen, G., Kajigaya, S., Young, N. S., & Maciejewski, J. P. (2006). Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood, 107, 167-175.
58. Nozawa, Y. (2002). Roles of phospholipase D in apoptosis and pro-survival. Biochimica et Biophysica Acta, Molecular Cell Biology of Lipids, 1585, 77-86.
59. Park, M. A., Lee, M. J., Lee, S. H., Jung, D. K., & Kwak, J. Y. (2002). Anti-apoptotic role of phospholipase D in spontaneous and delayed apoptosis of human neutrophils. FEBS Letters, 519, 45-49.
60. Helms, J. B., de Vries, K. J., & Wirtz, K. W. A. (1991). Synthesis of phosphatidylinositol 4, 5-bisphosphate in the endoplasmic reticulum of chinese hamster ovary cell. Journal of Biological Chemistry, 266, 21368-21374.
61. Hodgkin, M. N., Masson, M. R., Powner, D. J., Saqib, K. M., Ponting, C. P., & Wakelam, M. J. O. (2000). Phospholipase D regulation and localisation is dependent upon a phosphatidylinositol 4, 5-bisphosphate-specific PH domain. Current Biology, 10, 43-46.
62. Chen, G., Zeng, W., Maciejewski, J. P., Kcyvanfar, K., Billings, E. M., & Young, N. S. (2005). Differential gene expression in hematopoietic progenitors from paroxysmal nocturnal hemoglobinuria patients reveals an apoptosis/immune response in 'normal' phenotype cells. Leukemia, 19, 862-868.
63. Savage, W. J., Barber, J. P., Mukhina, G. L., et al. (2009). Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Experimental Hematology, 37, 42-51.
64. Heeney, M. M., Ormsbee, S. M., Moody, M. A., Howard, T. A., DeCastro, C. M., & Ware, R. E. (2003). Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria. Molecular Genetisc and Metabolism, 78, 291-294.
65. Horikawa, K., Nakakuma, H., Kawaguchi, T., et al. (1997). Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia and myelodysplastic syndrome. Blood, 90, 2716-2722.
66. Brodsky, R. A., Vala, M. S., Barber, J. P., Medof, M. E., & Jones, R. J. (1997). Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proceedings of National Academy of Science United States of America, 94, 8756-8760.
67. Bae, J., Hsu, S. Y., Leo, C. P., Zell, K., & Hsueh, A. J. (2001). Underphosphorylated BAD interacts with diverse antiapoptotic Bcl-2 family proteins to regulate apoptosis. Apoptosis, 6, 319-330.
68. Chen, L., Willis, S. N., Wei, A., et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecules and Cells, 17, 393-403.
69. Reimers, K., Choi, C. Y. U., Bucan, V., & Vogt, P. M. (2008). The Bax inhibitor-1 (BI-1) family in apoptosis and tumorigenesis. Current Molecular Medicine, 8, 148-156.
70. Nagakura, S., Ishihara, S., Dunn, D. E., et al. (2002). Decreased susceptibility of leukemic cells with PIG-A mutation to natural killer cells in vitro. Blood, 100, 1031-1037.
71. Jiang, H., Wu, Y., Liang, B., et al. (2005). An affinity/avidity model of peripheral T cell regulation. Journal of Clinical Investigation., 115, 302-312.